Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735363 | 0.92 | NPC1 (0.40) | NPC1RAB9ASCDMAPTMTOR | |
| SCHEMBL214760 | 0.92 | MEN1 (0.41) | PDE3BPDE3AMAPTDRD3DRD2 | |
| SCHEMBL4412205 | 0.90 | DRD3 (0.42) | NPC1RAB9AMAPTDRD3DRD2 | |
| SCHEMBL13320334 | 0.83 | MEN1 (0.41) | PDE3BPDE3AMAPTDRD3DRD2 | |
| SCHEMBL214368 | 0.82 | DRD3 (0.41) | PDE3BPDE3AMAPTDRD3DRD2 | |
| SCHEMBL2735429 | 0.81 | DRD3 (0.42) | NPC1RAB9AMAPTDRD3DRD2 | |
| SCHEMBL216183 | 0.81 | DRD3 (0.42) | NPC1RAB9AMAPTDRD3DRD2 | |
| Hydrochloric Acid SCHEMBL215263 | 0.81 | DRD3 (0.41) | NPC1RAB9AMAPTDRD3DRD2 | |
| SCHEMBL2735374 | 0.81 | LTA4H (0.42) | MAPTLTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL2735438 | 0.81 | LTA4H (0.42) | MAPTLTA4HALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | NPC1 3307/4885RAB9A 2213/4885PDE3B 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.